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Sandostatin (octreotide) is a registered trademark 
of Sandoz Pharmaceuticals Corporation, East 
Hanover, New Jersey. Sandostatin is also known 
as SMS 201-995, SMS, and somatostatin ana- 
logue. 
SMS 201-995 (Sandostatin) was studied using low doses (50 to 100 
pg) administered subcutaneously every 12 hours. A single 50-E.cg 
dose of SMS 201-995 effectively controlled gastric acid and blood 
gastrin levels for 12 hours in three patients with benign gastrinomas 
and was useful in their perioperative management. Higher doses of 
the agent (590 to 800 pg per day) had no effect on metastases in one 
of two patients with metastatic gastrinoma. In the other patient, one 
tumor shrank but the other continued to grow after three months of 
treatment while serum gastrin’levels did not change. Cultured meta- 
static tumor tissue from this patient released different forms of gas- 
trin; growth rates varied, independent of uptake of SYS 201-995, 
and gastrin release increased. A neonate with nesidioblastosis 
maintained normal blood glucose levels while receiving SMS 201- 
995 therapy following a 95 percent pancreatic resection. In twd el- 
derly patients with organic hypoglycemia-one with a single benign 
adenoma and one with multiple adenomatosis-the somatostatin 
analogue did not prolong the hypoglycemia-free interval. In nine 
patients with carcinoid syndrome, flushing was uniformly con- 
trolled with 50 pg of SMS 201-995 administered every eight to 12 
hours. One of the nine required exocrine pancreatic replacement. 
After six months of treatment, three of the nine had no change in 
tumor size and one had remission of symptoms and stopped treat- 
ment. In two patients with vipoma, SMS 201995 controlled diarrhea 
and reduced levels of vasoactive intestinal peptide; tumor necrosis 
occurred in one patient. In a patient with diabetic ‘diarrhea unre- 
sponsive to all treatments, SMS 201-995 therapy controlled the diar- 
rhea but did not interfere with control of the diabetes. 
Neuroendocrine tumors of’the gastroenteropancreatic axis (e.g., gastri- 
noma, insulinoma, somatostatinoma, vipoma, and ppoma, among others) 
are more frequently recognized now that their clinical features are better 
known and diagnostic methods have improved [l]. Although more than 
35 peptides are produced in the gastroenteropancreatic axis, only six 
clinical manifestations of hormone excess are currently recognized: pep- 
tic ulcers, diarrhea, dermatosis, diabetes, hypoglycemia, and flushing [2]. 
Neuroendocrine tumors may be c!inicalty silent but secrete gastroenter- 
opancreatic hormones, such as pancreatic polypeptide, that show little 
biologic activity [1,2]. Many of these syndromes are amenable to surgical 
or medical treatment [I ,2]. Surgical treatment, directed toward the target 
organ (e.g., the stomach in gastrinoma’syndrome), increases life expect- 
ancy. Early removal of the tumor may prevent death from tumor metasta- 
ses [3]. However, in some patients, the tumor cannot be removed and 
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available medical therapy for the symptom complex is in- 
adequate. 
The advent of histamine HZ-receptor antagonists revo- 
lutionized the management of gastrinoma syndrome [4], 
obviating the need for total gastrectomy in most cases 
[4-61. However, in 15 to 30 percent of patients, these 
drugs are not effective initially or ultimately fail [7,8]; thus, 
more potent antisecretory agents are being sought. In 
addition to controlling acid secretion, methods to treat the 
tumor are now being investigated since the incidence of 
gastrinoma metastases is between 60 and 90 percent 
[4,5,9], and 20 percent of patients die of metastatic dis- 
ease [lo]. 
In experimental animal and human studies, native so- 
matostatin-I4 was found to inhibit gastric secretion [ll- 
141; however, since its biologic half-life is short [15], it 
must be given continuously. Preliminary results with the 
long-acting somatostatin analogue SMS 201-995 in the 
management of gastric acid hypersecretion have been 
encouraging [16,17], and the drug may have potential as 
an anti-tumor agent in certain gastroenteropancreatic 
endocrine tumors [17-l 91. 
Organic hypoglycemia with hyperinsulinism is a rela- 
tively rare but well-described [20] syndrome that includes 
several pathologic states of the endocrine pancreas. The 
pathology dictates the type of therapy selected to prevent 
hypoglycemia and control hyperinsulinism if possible. 
Surgery is preferable for single adenomas because of the 
high cure rate. When surgery is not possible, medical 
management includes phenytoin [21,22], diazoxide, thia- 
zide diuretics [23,24], and beta blockers [25-271 to sup- 
press insulin release, but none of these is ideal and all are 
associated with significant side effects. These modalities, 
along with tumoricidal agents such as streptozotocin 
[28,29], 5-fluorouracil [30], and doxorubicin [31], are used 
to treat malignant insulinomas; the results are variable 
and the tumors may become refractory to these drugs. 
The carcinoid syndrome was recognized more than 75 
years ago, but the spectrum of amines and peptides pro- 
duced by these tumors is only now being explored. Car- 
cinoids are heterogeneous, multipotential lesions that are 
important in the pathogenesis of one or more symptoms, 
and are, therefore, markers of actively secreting tumors. 
The characteristic features of the carcinoid syndrome in- 
clude facial flushing, diarrhea, dyspnea on exertion, and 
bronchial spasm. The presence of a carcinoid tumor cor- 
relates with serum or plasma serotonin levels. 
Flushing, a transient reddening of the face and fre- 
quently the neck, upper chest, and epigastric area, is 
often the initial manifestation of endocrine tumors [l], no- 
tably carcinoid [32,33], but also pheochromocytoma [34] 
and medullary carcinoma of the thyroid [35]. A variety of 
vasoactive substances produced by carcinoids, including 
serotonin [36], catecholamines [I], prostaglandins [37], 
calcitonin [38], vasoactive intestinal peptide [39], sub- 
stance P [40], and motilin [41] cause the classic intermit- 
tent episodes of flushing that are biochemically and phar- 
macologicly heterogeneous [42]. 
Surgery to resect the tumor is the therapy of choice 
when the diagnosis can be confirmed and the tumor local- 
ized. When surgery is not possible, an accurate biochemi- 
cal and hormonal diagnosis is the key to rational medical 
treatment. However, management of patients who do not 
have distinct biochemical or hormonal abnormalities, or 
whose condition is refractory to standard treatment, is dif- 
ficult. Somatostatin and its analogues have been reported 
to block the spontaneous and pentagastrin-provoked epi- 
sodes of flushing in patients with carcinoid syndrome 
[43,44]. 
Diarrhea may be a prominent symptom in patients with 
carcinoid syndrome, medullary carcinoma of the thyroid, 
gastrinoma syndrome, and the vipoma syndrome. The 
mechanisms responsible for the diarrhea appear to be 
quite different for these conditions [1,2]. In the gastrinoma 
syndrome, it appears to be gastric acid hypersecretion 
with damage to the small intestine mucosa, inactivation of 
enzymes, and precipitation of bile salts. The diarrhea of 
the gastrinoma syndrome is unique in that it responds to 
HZ-receptor blocking drugs; however, symptomatic con- 
trol may not be achieved in all patients. In the other condi- 
tions, the diarrhea is usually secretory, will not disappear 
with fasting, and causes a net secretion of fluid and elec- 
trolytes, confirmed by small bowel secretion studies. The 
agents used to manage secretory diarrhea produce varia- 
ble results [2]. 
The “diabetic diarrhea” seen in patients with labile, 
poorly controlled, long-term, insulin-requiring or insulin- 
dependent diabetes coexisting with peripheral and/or au- 
tonomic neuropathy occasionally responds to treatment 
with antidiarrheal agents, antimicrobial agents, pancreatic 
enzyme, bile acid exchange resin, and clonidine, given 
alone, or in combinations [45-471. 
The effect of SMS 201-995 on diarrhea refractory to all 
forms of therapy in a variety of endocrine tumors and in a 
patient with insulin-dependent diabetes is reported. 
GASTRINOMA SYNDROME 
The clinical details of five patients with gastrinoma syn- 
drome are summarized in Table I. 
Benign. Patients 1, 2, and 3 had hypergastrinemic hy- 
perchlorhydria and benign gastrinomas, one in the duode- 
nal wall, one in a peripancreatic lymph node, and one 
within the liver, localized preoperatively by percutaneous 
transhepatic venous sampling [3]. Their gastric acid se- 
cretory response to various forms of treatment was stud- 
ied. After an overnight fast and withdrawal of HZ-blockers 
and other antisecretory agents for 24 hours, a nasogastric 
tube was placed in the stomach (its position was con- 
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TABLE I Clinical Features of Five Patients with Gastrinoma Syndrome 
Case Age 
Number (years) Sex Symptoms/Duration Tumor 
&cretin Test 
Basal Acid Output/ 
Maximal Acid Output Basal Peak 
(meq/hour) Gastrin (pg/ml) Prior Treatments 
1 61 F Diarrhea, weight loss 
(3 months) 
2 55 M Nausea, vomiting, ulcer 
disease, bleeding 
(10 years) 
3 43 M Diarrhea (2 years) 
4 38 M Abdominal pain, weight 
loss, ulcer disease 
(6 years) 
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BCNU = 1,3-bis(2-chloroethyl)-l-nitrosourea, carmustine. 
firmed fluoroscopically), and gastric aspiration was a- 
chieved by continuous suction using a negative pressure 
pump. 
Using a crossover design, the three patients were ran- 
domly given subcutaneous injections of SMS 201-995, 50 
to 100 pg per day, every six to 12 hours for up to 48 hours, 
followed ‘by a 24-hour washout period, and then either 
normal saline or cimetidine, 200 to 1,2QO mg intrave- 
nously, every four to six hours for 12 to 48 hours. Gastric 
juice and blood samples were collected during a four-hour 
baseline period, and at four-hour intervals during adminis- 
tration of the study agents. 
The gastric secretory response to the treatment regi- 
mens was similar in the three patients (Figure 1). In con- 
trast to either nqrmal saline or cimetidine, SMS 201-995 
lowered serum gastrin and reduced gastric acid secretion; 
the response was dose-related, with a greater response to 
100 pg given every six hours than to 50 pg given every 12 
hours. In Patient 1, who received 100 pg of the somato- 
statin analogue every six hours, gastric secretion was 
completely inhibited eight hours after the first injection: 
gastric pH rose from 1.2 to 7.6, acid output dropped to 
zero, gastric secretory volume decreased comparably, 
and the patient’s gastrin level returned to normal. 
Patients 1 and 2 received 50 pg of SMS 201-995 su.b- 
cutaneously on the morning of their surgical procedure to 
suppress gastric acid secretion and to counteract the loss 
of large volumes of acid and Severe metabolic alkalosis 
resulting from continuous gastric aspiration. In Patient 2, a 
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postoperative rebound in gastric acid secretion occurred 
despite continued administration of the analogue, 50 pg 
every six hours. However, increasing the dose resulted in 
a significant reduction in the daily volume of gastric aspi- 
rate over six days; the patient showed marked improve- 
ment and oral feeding was resumed. 
In Patient 3, one 1 00-pg subcutaneous injection of SMS 
201-995 markedly reduced blood flow to the tumor (Fig- 
ure 2), and within 15 minutes right hepatic vein gastrin 
decreased to normal levels. 
Metastatic. Patients 4 and 5 had hepatic metastases 
from an unidentified primary focus. Each had had a total 
gastrectomy, partial pancreatectomy, and chemotherapy, 
but both showed clinical and radiologic evidence of pro- 
gressive tumor enlargement. They were entered into our 
study protocol for three to six months, and were followed 
clinically at two- to four-week intervals for routine bio- 
chemistry and serum gastrin determinations. Computer- 
ized axial tomographic scans (CT scans) were obtained 
every three months. 
In Patients 4 and 5, blood samples for gastrin were ob- 
tained every four hours, starting eight hours before and 
continuing for 48 to 96 hours, for each SMS 201-995 dos- 
age used. Dosage was titrated over three to six months 
based on serum gastrin levels, with normal gastrin levels 
as the clinical goal. Only a modest decline in gastrin levels 
for up to 12 hours occurred following the short-term sup- 
pression test with SMS 201-995. 
During the initial three months of therapy, Patient 4 re- 
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gure 1. Gastric acid responses (acid output, top; serum 
gastrin, bottom) to saline, cimetidine, and SMS 201-995 in 
patients with benign gastrinoma. 
ported feeling better; but even with increasing doses, 
serum gastrin levels did not return to normal. At the end of 
three months, a left lobe hepatic metastasis was found to 
be growing (“big tumor”), while another metastatic tumor 
in the right lobe was regressing (“small tumor”). The two 
tumors were resected and therapy with SMS 201-995 was 
continued perioperatively. Portions of the two tumors were 
extracted as previously described [48] to determine gas- 
trin, somatostatin, and SMS 201-995 content. Somato- 
statin analogue content was determined by a recently 
described radioimmunoassay from the laboratory of Dr. 
Thomas M. O’Dorisio at the Ohio State University. This 
assay has been shown to be non-cross-reactive with en- 
dogenous native somatostatin [49]. 
Five hours after subcutaneous administration of 100 pg 
of SMS 201-995, the drug concentration in the “big tumor” 
was 126 nglg net weight. The analogue’s concentration in 
the “small tumor” was 72 rig/g net weight six hours after 
the injection. Results of in vitro studies of these tumors 
with and without SMS 201-995 are shown in Table II. In- 
creasing concentrations of the analogue, from 0.5 to 5 
pg/ml, paradoxically increased the gastrin content in the 
media for the “big tumor” at all doses. In the “small 
tumor,” gastrin decreased slightly with 5.0 pg/ml of SMS 
201-995. On chromatographic analysis of extracted gas- 
trin, the predominant form was gastrin-17 in the “big 
tumor” and gastrin-34 in the “small tumor.” 
Over six months, progressive enlargement of hepatic 
metastases occurred in Patient 5, who was treated with up 
to 500 pg of SMS 201-995 per day, but CT scans showed 
progressive enlargement of hepatic metastases 
(Figure 3). Cytotoxic treatment was reinstituted. 
HYPERINSULINISM 
Benign Insulinomas. Patient 1 (TS) is a 33-year-old 
man who first experienced symptoms of symptomatic 
hypoglycemia in December 1982. In December 1984, dur- 
ing a second episode of hypoglycemia, his blood glucose 
was 21 mg/dl. Following a prolonged 14-hour fast, it 
dropped to 39 mgidl. lmmunoreactive insulin measured 
simultaneously was 26 pU/ml and the calculated insulin/ 
glucose ratio was 0.7 (normal less than 0.3). Pertinent 
laboratory findings included a negative insulin antibody, a 
negative beta-human chorionic gonadotropin, and normal 
levels of prolactin, gastrin, and pancreatic polypeptide. CT 
scans of the abdomen were unremarkable. Mesenteric 
angiography disclosed a 3-cm vascular tumor in the isth- 
mus of the pancreas. 
Preoperatively, the patient fasted twice. During the first 
fast, no drug was given. During the second, 100 pg of 
SMS 201-995 was given subcutaneously every 12 hours. 
Plasma samples were obtained every four hours to mea- 
sure levels of glucose, insulin, glucagon, proinsulin, and 
C-peptide. Immediately prior to surgery, the patient was 
given a subcutaneous injection of 50 pg of the analogue. 
His blood glucose was monitored intraoperatively. During 
surgery, his blood glucose was maintained at a mean of 
161 i 26 mgidl without the aid of intravenous glucose. 
The immediate postoperative blood glucose value was 
156 mg/dl. 
During surgery, the body and tail of the pancreas were 
found to be normal. A 3-cm mass was found in the un- 
cinate process of the pancreas, which was impinging on 
the duodenum. The tumor was difficult to enucleate 
cleanly, but was completely removed in a piecemeal fash- 
ion. Pancreatic ducts could not be identified in the tumor 
or in the remaining pancreatic tissue. Granules of immu- 
noreactive insulin and serotonin were observed, but no 
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Figure 2. Responses of blood flow to an 
intrahepatic gastrinoma before (A) and 
after (6) the administration of SMS 201- 
995. Arrows indicate the tumor blush. 
Figure 3. Computerized tomographic scans before (A) and after eight (6) and 11 (C) months of SMS 201-995 treatment 
showing progression of a metastatic gastrinoma. 
other gastrointestinal polypeptides were found by immu- TABLE II Tumor Content of Somatostatin and SMS 
nohistochemical staining. 201-995 and in Vitro Release of Gastrin 
Following surgery, symptomatic hypoglycemia devel- 
oped in the patient, who had a measured blood glucose 
level of 41 mgidl after fasting for 16 hours. After adminis- 
tration of 100 pg of SMS 201-995 every 12 hours, he was 
able to fast for 44 hours before becoming hypoglycemic, 
and his insulin level was suppressed to 25 percent of the 
basal value. C-peptide levels declined in parallel with the 
insulin levels. Glucagon dropped to one-third the fasting 
basal value, but rose towards baseline after 48 hours of 
treatment with the analogue (Figure 4). 
Large Tumor Small Tumor 
Patient 2 (GL), a 59-year-old white woman, was admit- 
ted with a three-year history of hypoglycemic episodes. A 
previous workup revealed a vascular blush in the distal 
Tumor content 
(ngig tissue wet weight) 
Somatostatin 
SMS 201-995 
Release of gastrin 
(rig/g tissue wet weight/4 hours) 
Without SMS 201-995 
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Figure 4. Effects of fasting in a patient with a benign single 
insulinoma with (solid circks) and without (open circles) 
SMS 201-995. 
pancreas consistent with an insulinoma. The patient was 
pretreated with SMS 201-995 and underwent resection of 
a 1.5 x 2 cm neoplasm in the distal pancreas under gen- 
eral anesthesia. The blood glucose and insulin responses 
in the perioperative period are shown in Figure 5. 
Patient 3 (MP), an 82-year-old man, had a three-year 
history of episodes of sweating, palpitations, hunger, and 
mental confusion, which could be relieved by eating or 
drinking juice. He experienced episodes of uncontrolled 
motion of the arms and legs, clenched jaw, and occa- 
sional incontinence occurring between 3:00 and 6:00 
A.M.; these symptoms could be prevented by eating every 
four to five hours. In October 1985, he had a fasting glu- 
cose level of 36 mg/dl and an insulin level of 38 @/ml. 
When admitted to the University of Michigan Hospital, 
he was in good health except for mild hypertension, atrial 
fibrillation, and some congestion at the bases of the lungs. 
In the preceding year, he had been treated for prostatic 
cancer with prostatectomy and 37 external radiation treat- 
ments. During this time, he had gained 10 pounds and his 
fasting glucose level was 36 mg/dl while his insulin level 
was 38 PUIml. The fasting blood glucose level on admis- 
sion was 40 mg/dl after a nine-hour fast, with an insulin 
value of 55 @J/ml, 55 percent of which was proinsulin. He 
perspired profusely and became quite confused. The re- 
sults of both CT and (nuclear) magnetic resonance imag- 
ing (MRI) examinations were negative. A celiac axis angi- 
ogram and portal venous sampling indicated a tumor at 
the junction of the head and neck of the pancreas. A 
course of SMS 201-995 therapy had no effect on his blood 
glucose control. The drug was discontinued and diaz- 
oxide, 300 mg per day, and hydrochlorothiazide, 150 mg 
per day, were given; blood glucose levels improved and 
the interval between required food intake decreased from 
two to six hours (Figure 6). However, after 10 days on this 
regimen, he gained 18 pounds, incipient cardiac failure 
developed, and he was hospitalized. He underwent lapa- 
rotomy and a benign adenoma at the junction of the head 
and neck of the pancreas was resected. 
Nesidioblastosis. Hypoglycemia developed 40 minutes 
after delivery in Patient 4 (baby H), a male infant born at 
37 weeks gestation by uncomplicated vaginal delivery. 
Glucose was given, but blood glucose levels ranged from 
30 to 45 mgidl, and he experienced recurrent seizures 
due to hypoglycemia. The infant was referred to Dr. Jef- 
frey Jackson at the A and M Medical Campus in Temple, 
Texas. Even with a glucose infusion rate of 22 mg/kg per 
minute, blood glucose levels dropped to the 35 to 50 mg/dl 
range. Insulin levels were 92 and 40 plJ/ml with blood 
glucose levels of 16 and 17 mgidl, respectively. Diazoxide 
was initiated 14 days postpartum but had no effect on 
blood glucose levels. The diagnosis of nesidioblastosis 
was made and the patient underwent 90 percent pancrea- 
tectomy on the 19th day. 
During the postoperative period, blood glucose gradu- 
ally declined to below 50 mg/dl necessitating glucose infu- 
sion, although the insulin level had fallen from 80 to 20 
$Jlml. SMS 201-995 was started on Day 27, with an initial 
dose of 25 pg twice daily. Within the first five hours, a 
reduction in the glucose infusion rate was possible without 
hypoglycemia developing. The infusion was eventually 
stopped on Day 33 with blood glucose levels generally 
above 50 mg/dl. The insulin levels dropped to 13 pU/ml on 
Day 42 and finally to 8 plJ/ml on Day 59. Oral feedings 
were started, but the patient had bouts of diarrhea, which 
were controlled by pancrelipase. He gained 1.5 pounds 
after starting therapy with the analogue and had a normal 
increase in body length and head circumference. His 
maintenance dose of SMS 201-995 is 30 pg twice daily 
(Jackson VA, et al: Treatment of refractory neonatal hypo- 
glycemia and nesidioblastosis with a long-acting somato- 
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statin analogue [compound 201-9951. Presented at the 
International Conference on Somatostatin, Washington, 
DC, May 6-8, 1986). 
Multiple Adenomas. Patient 5 (LW), a 72-year-old 
slightly overweight white woman with a history of non- 
insulin-dependent diabetes mellitus and hypertension for 
the past eight years, had been receiving 250 mg of chlor- 
propamide and hydrochlorothiazide daily until two months 
'E 
prior to her referral to the University of Michigan Hospital. 0 
She was referred because of a suspected episode of tran- 
sient neurologic deficit early in the morning, followed two 50 
weeks later by a diagnosis of hypoglycemia based on a 3 
z 
recent fainting spell at 3:00 A.M., at which time her blood 
% 
E 
glucose level was 38 mg/dl. Chlorpropamide had been 
discontinued four weeks earlier. 
When evaluated, her blood glucose level was 34 mgidl 
after a four-hour fast and 53 mg/dl after six to nine hours 
with an insulin level of 207 @J/ml; at 13 hours, the blood 
glucose level was 30 mg/dl with an insulin level of 128 
@/ml; and after 19 hours, the blood glucose level was 30 
mg/dl with an insulin level of 154 PUlml, and she was 
sweating profusely and had become disoriented. Proinsu- 
lin constituted 58 percent of the total insulin value (normal 
less than 22 percent) and CT and MRI examinations failed 
to disclose a tumor. A celiac axis angiogram showed two 
areas in the head and tail of the pancreas that were sus- 
0 
250 





a single benign insulinoma. 
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‘igure 5. Successful use of SMS 201-995 in a patient with 
Figure 6. Twenty-four-hour glucose pro- 
file in a 82-year-old patient with a single 
benign insulinoma. Note that SMS 201- 
995 raised the blood glucose responses 
to the morning meal but failed to prevent 
later hypoglycemia, whereas diazoxide 
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petted of being tumors. Simultaneous transhepatic portal 
venous sampling confirmed the presence of at least two 
step-ups in the insulin concentration in the venous drain- 
age areas of the head and tail of the pancreas. Three 
months later, a trial of SMS 201-995 therapy resulted in 
more severe hypoglycemia. The analogue was stopped 
and replaced with 200 mg of diazoxide per day and 
150 mg of hydrochlorothiazide, which maintained eugly- 
cemia. After 10 days of treatment, anasarca and conges- 
tive cardiac failure developed and she was admitted to the 
hospital for definitive treatment of her organic hyperinsu- 
linism. 
CARCINOID SYNDROME 
At the University of Michigan, between 1959 and 1981,35 
cases of the carcinoid syndrome associated with carcinoid 
tumors were seen. Urine 5-hydroxyindoleacetic acid (5- 
HIAA) levels were abnormally elevated in 23 cases; all 
had metastases. Serum 5-hydroxytryptamine (serotonin) 
levels were found to be abnormally high in 26 patients. A 
rough correlation between the urinary level of 5-HIAA and 
tumor size was demonstrated. 
Patient 1 (EP), a 58-year-old woman, presented with 
bowel obstruction. Laparotomy revealed a tumor in the 
small bowel causing obstruction and multiple enlarged 
mesenteric lymph nodes and liver lesions. Pathologic 
examination showed a multicentric carcinoid tumor with 
transmural invasion of the small bowel and metastasis to 
two of 10 mesenteric lymph nodes and to the liver. Follow- 
ing surgery, she underwent l-131 meta-iodo benzyl- 
guanidine scan to evaluate the possibility of radioisotope 
treatment, but the scan did not reveal liver or mesenteric 
metastases. A gastrointestinal hormone screen revealed 
elevated serotonin (1 ,125 rig/ml) and slightly elevated 
gastrin (158 pg/ml) levels. Subcutaneous injections of 
SMS 201-995, 50 pg twice daily, were started, and 10 
months later the dosage was gradually increased to 150 
pg twice daily without a significant drop in the serotonin 
level. Abdominal CT scans showed no change in size of 
the diffuse liver metastases. 
Patient 2 (CS), a 61 -year-old white man, was diagnosed 
as having carcinoid syndrome with metastases. He had 
repeated episodes of periumbilical pain with heme-posi- 
tive stools but an upper and lower gastrointestinal series 
were negative. A CT scan of the abdomen showed a sub- 
pleural nodule in the lower lung field on the right and low 
attenuating lesions in the liver. Celiac axis angiogram indi- 
cated a vascular blush in the small bowel region. Urinary 
5-HIAA levels were elevated. Laparotomy revealed a 
6-cm mass in the distal ileal mesentery, which was re- 
sected along with three feet of bowel, and an end-to-end 
anastomosis was done. Multiple liver metastases were 
noted. Four months later, a hepatic artery pump was 
placed and five fluorodeoxyuridine treatments were given 
over four weeks. He continued to have intermittent diar- 
rhea and repeated episodes of flushing, but no pulmonary 
hypertension and no increase in skin pigmentation devel- 
oped. Telangiectasia occurred on the face, upper trunk, 
and forearms. The results of cardiac, pulmonary, and ab- 
dominal examinations were negative. Hemoglobin was 
12.9 gidl, alkaline phosphatase was 381 U/ml, and sero- 
tonin was 981 rig/ml (normal, 30 to 200 rig/ml); gut hor- 
mone levels were within normal limits. 
Three months later, treatment was begun with SMS 
201-995, 50 pg twice daily, and continued for three 
months; however, symptoms were not controlled and the 
dose was increased to 150 pg twice daily. After three 
months at the higher dose, serotonin levels fell to 211 
rig/ml and symptoms virtually disappeared; however, after 
five months at the higher dose, the multiple hepatic me- 
tastases had not changed in size on CT examination. 
Patient 3 (JB), a 58-year-old man with a diagnosis of 
carcinoid syndrome, had a two-year history of mild hyper- 
tension, diarrhea, and flushing spells and a 24-hour uri- 
nary 5-HIAA output of 78 mg (normal, 3 to 10 mg). Upper 
gastrointestinal endoscopy was unremarkable, but ultra- 
sound revealed a large mass in the right lobe of the liver. 
Visceral angiography confirmed the presence of a hyper- 
vascular mass in the right lobe of the liver as well as multi- 
ple small masses scattered throughout the remainder of 
the liver. Laparotomy revealed a small primary tumor in 
the terminal ileum with significant involvement of the mes- 
enteric nodes and a large secondary tumor in the liver. All 
were resected and found to be histologically compatible 
with carcinoid. The patient did well postoperatively, but 
after five months, flushing returned, one to two times 
every two to three days, and the frequency of watery 
stools increased. Treatment with SMS 201-995, 50 pg 
every eight hours, was started and an immediate improve- 
ment in diarrhea and flushing was noted. The tumor did 
not respond; serotonin was 981 rig/ml, the gut hormone 
profile was normal, and alkaline phosphatase was 381 IU/ 
ml. Eight months later, the dose was increased to 150 Fg 
every eight hours; after five months, the serotonin con- 
centration fell to 211 IU and the alkaline phosphatase 
level to 217 IU/ml, but the liver tumor mass did not pro- 
gress after 10 months of SMS 201-995 therapy (Fig- 
ure 7). 
DIARRHEA 
Table Ill illustrates the effect of a single 50-pg dose of 
SMS 201-995 on water and electrolyte transport in the 
small intestine in three patients with chronic diarrhea. 
Vipoma. A 54-year-old woman was referred to the Uni- 
versity of Michigan Hospital with a five-year history of re- 
fractory diarrhea and a 50-pound weight loss. She had 
required hospitalization several times for fluid and electro- 
lyte imbalance resulting from uncontrollable diarrhea and 
vomiting. Fourteen months previously, a CT scan of the 
abdomen showed multiple liver metastases. Subsequent 
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Figure 7. Arrest of progression of a he- 
patic metastasis from an appendiceal 
carcinoid metastatic to the liver after 70 
months of treatment with SMS 207-995. 
TABLE III Small Intestine Water and Electrolyte Movement in Three Patients with Chronic Diarrhea* 
Diagnosis Water Sodium Chloride Potassium Bicarbonate 
Vipoma 
-SMS +51 .O t 65.5 +6.7 k 9.6 +7.8 + 8.9 -0.2 2 0.2 -1.0 * 1.5 
+SMS+ -136.0 i 46.6’ -20.0 k 4.0* -13.4 i- 3.9* -0.9 f 0.2* -6.2 k 0.e 
Substance Poma 
-SMS -93.6 k 41.3 -12.4 ” 5.8 -4.9 2 3.7 -0.8 2 0.2 -13.8 t 12.6 
+SMS -87.6 2 40.2 -12.8 ” 5.5 -7.7 2 4.9 -0.7 f 0.2 -6.1 + 0.9 
Diabetic enteropathy 
-SMS -54.3 ? 49.7 -8.0 t- 7.5 -4.7 2 6.2 -0.2 t 0.4 NA 
+SMS - 134.2 k 60.1 -15.8 t 8.5 -12.1 i- 6.7 -0.7 2 0.2 NA 
NA = not applicable. 
‘Perfusate (isotonic solution): sodium, 140 mM; potassium, 5 mM; chloride, 110 mM; bicarbonate, 35 mM; pH 8.1; polyethylene glycol, 5 g/liter. 
Normal range: water, - 15 to - 115 ml/hour/30 cm; sodium, -4.1 to -16.5 meqlhouri30 cm; chloride, -0.4 to -14.7 meq/hour/30 cm; potassium, 
+0.2 to -0.7 meqihouri30 cm; bicarbonate, -1.7 to -7.4 meqihouri30 cm. Values are mean k SE of three to five measurements; + = net 
secretion, - = net absorption. 
++SMS refers to response to subcutaneous administration of 100 pg of SMS 201-995 (Sandoz, Inc.) 
*p CO.05. 
liver biopsy eight months later suggested adenocarci- 
noma, and a five-month course of chemotherapy with 
5fluorouracil was initiated. Following chemotherapy, the 
findings of a repeat liver biopsy was consistent with carci- 
noid; plasma serotonin levels were normal. One month 
later, her plasma vasoactive intestinal peptide level was 
found to be markedly elevated (1 ,I 63 pgiml; normal below 
170 pg/ml) and the diagnosis of vipoma was made. 
When admitted to the University of Michigan Hospital, 
she was cachectic and dehydrated. The liver was en- 
larged and had a hard irregular consistency. Liver and 
renal function were normal with moderate hypokalemia. 
Hormone values were as follows: vasoactive intestinal 
polypeptide, 688; gastrin, 91; somatostatin, 123; pancre- 
atic polypeptide, 715 pg/ml; growth hormone, 11 .Q; pro- 
lactin, 27 rig/ml; parathyroid hormone midportion, 134, 
and N-terminal 14 ngeq/ml; and calcium, 11 mgldl. 
Her hospital course was complicated by watery diar- 
rhea of up to 9 liters per day with marked hypokalemia and 
bicarbonate wasting. Intravenous hyperalimentation and 
subcutaneous administration of SMS 201-995, 100 pg per 
day, were initiated. The drug dose was gradually in- 
creased to 200 pg four times per day. The response to 
SMS 201-995 was impressive; bowel movements were 
reduced to one to two formed stools per day. Stool volume 
decreased to less than 500 ml per day, weight increased 
steadily, and potassium bicarbonate concentration re- 
turned to normal. CT scans showed massive tumor re- 
placement of the liver. Treatment with the analogue, 200 
pg four times per day, was continued for two months and 
then the dose was reduced to 100 pg four times per day. 
Levels of vasoactive intestinal polypeptide dropped to 160 
pg/ml, those of pancreatic peptide to 186 pg/ml, and those 
of endogenous somatostatin to 18 pg/ml. She was read- 
mitted two months after discharge with increasing abdom- 
inal pain and fever. Repeat CT scans (Figure 8) showed 
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Figure 8. 
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massive tumor necrosis. She underwent laparotomy and 
approximately 750 ml of necrotic tissue was evacuated 
from the liver and found to be histologically compatible 
with a neuroendocrine tumor. Gram-negative organisms 
were found in the necrotic tissue. Her postoperative re- 
covery was uneventful, and she has no diarrhea. The 
most recent level of vasoactive intestinal polypeptide was 
209 pg/ml (Figure 9). 
We believe that the somatostatin analogue controlled 
the diarrhea, lowered hormone levels, and might have 
been responsible for infarction of the tumor. We suggest 
that SMS 201-995 might act directly to decrease tu- 
mor blood flow and that its use in patients with tumors 
refractory to conventional chemotherapy might be 
warranted. 
Diabetic Diarrhea. A 39-year-old woman was admitted 
with progressive watery diarrhea unresponsive to treat- 
ment. She had a 17-year history of poorly controlled in- 
sulin-dependent diabetes mellitus complicated by retinop- 
athy, nephropathy, peripheral and autonomic neuropa- 
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thies, and a below-the-knee amputation for vascular dis- 
ease. Her autonomic neuropathy was manifested by pos- 
tural hypotension, gastroparesis, and a neurogenic blad- 
der. She had intermittent bouts of loose bowel movements 
for 10 years, which responded to antispasmodics and an- 
tidiarrheal agents. Fifteen months prior to admission, pro- 
fuse, painless, watery diarrhea developed with an in- 
creased frequency of up to 15 times per day and a daily 
stool output of 5 to 6 liters. The explosive episodes of 
diarrhea prevented a normal social life. The stools were 
free of blood, pus, and mucus, and tests for occult blood, 
leukocytes, culture, ova, parasites, and laxatives were 
negative. Stool osmolality was 317 mOsm/kg, and 24- 
hour fecal fat was 62 g. She reported a 20-pound weight 
loss during the last year, but no history of foreign travel or 
laxative abuse. Treatment with diphenoxylate, lopera- 
mide, psyllium hydrophilic mucilloid, and pancrelipase 
failed to control the diarrhea. However, while maintained 
on central hyperalimentation and bowel rest, her stool vol- 
ume declined to 400 to 600 ml per day, and she regained 
her previous weight. 
Plasma concentrations of vasoactive intestinal polypep- 
tide, motilin, somatostatin, serotonin, substance P, pan- 
creatic polypeptide, and calcitonin were normal; the re- 
sults of the secretin test (1 ,112 to 1,816 pg/ml) were posi- 
tive, and basal hypergastrinemia (232 to 24,768 pgiml) 
was present. Basal hypochlorhydria was unresponsive to 
betazole or pentagastrin. Serum gastrin was suppressed 
by continuous intragastric infusion of 0.1 N hydrochloric 
acid (1,385 to 593 pgiml). 
Findings on radiologic examination were normal except 
for the presence of retained gastric contents and some 
dilated loops of small bowel. Radionuclide study con- 
firmed the clinical diagnosis of gastroparesis. A pancreatic 
function test showed decreased trypsin and lipase re- 
sponses to stimulation by cholecystokinin. Hydrogen 
breath tests yielded abnormal findings in the basal state 
and after lactose challenge. The results of the Schilling 
and D-xylose tests were normal. 
The patient consented to a trial of 50 Fg of SMS 201- 
995 given twice daily, which was increased to 75 pg twice 
daily, given with her insulin injection 30 minutes before 
breakfast and dinner. On a regular diabetic diet plus 
Isotein, within 10 days of initiation of treatment with SMS 
201-995, stools were semi-formed and stool volume was 
reduced to 400 to 800 ml per day. During the outpatient 
phase of the study, the patient monitored her blood sugar 
and stool frequency and character. During maintenance 
therapy with the analogue, bowel movements decreased 
to one or two per day; stools were usually semi-formed, 
diabetic control was stable, and the daily insulin require- 
ment was essentially unchanged over a four-month 
follow-up period. The drug was well tolerated, and neither 
gastroparesis nor postural hypotension was aggravated 
(Figure 10). 
SMS 1 200 I 400 I 
Hours 0 4 6 12 1620 0 4 8121620 0 4 6 1216 
Days 1 2 3 
Figure 9. Responses of vasoactive intestinal peptide levels 
to treatment with SMS 201-995 in a patient with a metastatic 
vipoma. The decline in vasoactive intestinal peptide levels 
coincided with a disappearance in diarrhea. 
I 
Figure 10. Clinical course of a diabetic patient with diar- 
rhea that had persisted for 10 months and the response to 
differential treatment modalities. Vertical dashed line indi- 
cates the start of SMS 201-995 treatment. BW = body 
weight; EM = bowel movement; BS = blood sugar. 
I 
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COMMENTS 
Our objective in these studies was to determine if SMS 
201-995 could control hormone-amine action at target tis- 
sues and limit excessive hormone production by the tu- 
mors of the gastroenteropancreatic axis, and to evaluate 
the analogue’s effectiveness in regulating exocrine secre- 
tions by the gastrointestinal tract and the growth and dif- 
ferentiation of a number and variety of these tumors. 
The gastrinoma syndrome is heterogeneous, compris- 
ing at least four clinical entities: (1) G-cell hyperfunctioni 
hyperplasia, (2) benign sporadic gastrinoma, (3) gastri- 
noma with multiple endocrine neoplasia type I, and 
(4) metastatic gastrinoma [50,51]. Today, no single thera- 
peutic intervention is universally applicable to this hetero- 
geneous syndrome [l-3]. The use of native somatostatin- 
14 or somatostatin-28 to treat gastrinoma syndrome 
would require constant intravenous infusion [52]. A single 
injection of 100 pg of the long-acting somatostatin ana- 
logue inhibited pentagastin-stimulated gastric acid secre- 
tion in six healthy subjects [53]. Furthermore, in three pa- 
tients with gastrinomas, 50 pg of SMS 201-995 produced 
an inhibition of gastric acid secretion and a parallel decline 
in serum gastrin levels [54]. Two fresh tumors from these 
patients were studied in vitro in a cell dispersion prepara- 
tion, and SMS 201-995 reduced calcium-stimulated gas- 
trin release by 50 percent in a dose-dependent manner 
[54]. Data on tumor progression have not been reported. 
In our three patients with benign gastrinoma in whom 
acid secretion was not controlled by Hz-blockers, SMS 
201-995 in doses of 50 to 100 pg every six to 12 hours 
suppressed gastric secretion and acid output by 85 and 
95 percent, respectively. The rapid and complete inhibi- 
tion of gastric acid secretion led to a striking clinical im- 
provement and made surgery possible without other pre- 
operative treatment. Nasogastric suction resulted in se- 
vere hypochloremic alkalosis; a single 50-pg injection of 
SMS 201-995 controlled acid secretion for the duration of 
the procedure. Acid secretion must be suppressed before 
nasogastric suction is begun. No anesthetic problems 
were encountered, hypotension did not occur, and the 
blood glucose level remained stable throughout the pro- 
cedure. In Patient 2, after complete excision of the tumor, 
acid secretion did not immediately return to normal de- 
spite an appreciable lowering of serum gastrin. The dose 
of the analogue had to be increased to 800 pg per day 
and continued through the 7th postoperative day before 
gastric acid output was controlled. The patient did recover 
and remains free of ulcer symptoms or diarrhea. Why the 
patient’s condition became refractory to SMS 201-995 
during the postoperative period is difficult to explain. While 
large quantities of tumor gastrin could have been released 
during surgery, and exceeded the inhibitory capacity of 
the lower doses of SMS 201-995, the longest half-life of 
known gastrin peptides is about 40 minutes, which would 
make this an unlikely cause for the persistently high gas- 
tric acid secretion. Gastrin precursors with a half-life con- 
siderably in excess of that of G34 or G17 may have been 
released, but we have no data to confirm or refute this. An 
alternate explanation is that the tumor contained an inhibi- 
tor of acid secretion, such as somatostatin-14 or -28, 
which was simultaneously removed with the source of 
gastrin, thus unleashing acid secretion. However, the 
measured levels of circulating somatostatin did not sup- 
port this. 
These patients were treated with SMS 201-995 and 
surgery may now be a valid option. However, the long- 
term safety of the drug, especially in patients with gastri- 
noma syndrome who probably require life-long antisecre- 
tory agent(s), remains to be established. 
In patients with surgically inaccessible or metastatic 
tumors, the situation is quite different. At least 60 percent 
of gastrinomas are malignant and, at operation, more than 
50 percent have already metastasized to the liver [l-3]; 
the tumor, therefore, is the major threat to survival for pa- 
tients with malignant gastrinoma since gastric acid hyper- 
secretion is associated with reduced morbidity and mor- 
tality [3,7]. 
Various drugs and specific chemotherapeutic agents 
such as streptozotocin [55,56], 5fluorouracil [56,57], dox- 
orubicin [2], tubercidin [58], or radiation [59] have been 
used to manage unresectable or metastatic gastrinomas. 
These therapeutic modalities may provide palliative relief 
for some patients, but the overall results have been disap- 
pointing. Both experimental [60] and clinical findings 
[18,19] suggest that SMS 201-995 may be useful hor- 
monal therapy for some malignant gastroenteropancreatic 
endocrine tumors. In two vipoma cases, the analogue not 
only controlled the diarrhea, but also induced a shrinkage 
of liver metastases after five and 14 months of treatment 
[18,19]. In contrast, two patients with metastatic gastri- 
noma unresponsive to chemotherapy did not show a re- 
sponse to SMS 201-995; neither tumor growth nor the 
serum gastrin levels were controlled. However, one gas- 
trinoma patient (Patient 4) who showed a response to 15 
courses of chemotherapy and remained well for five 
years, also had a response to SMS 201-995. In fact, after 
three months of treatment with the analogue, one tumor 
shrank but another continued to grow. Although the 
patient’s amino-terminal/carboxy-terminal gastrin (NH2: 
COOH) ratio was abnormally high when his disease was 
active, it dropped when he was in remission. This sug- 
gests that metastases may process gastrin differently; 
the “small (regressing) tumor” contained predominantly 
G-34, while the “big (growing) tumor” contained predomi- 
nantly G-l 7. Whether this reflects a transcriptional event, 
mutation in the gastrin gene, or post-transcriptional pro- 
cessing clearly needs to be studied. Our data indicate that 
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metastatic tumors with a high NH2:COOH ratio are un- 
likely to respond to the somatostatin analogue. 
The mechanism of action of SMS 201-995 may not be a 
direct effect, but rather may be mediated indirectly. Incu- 
bation of the metastatic tumor with the analogue stimu- 
lated the release of gastrin, in contrast to the observed 
inhibition of gastrin release in benign gastrinoma [54]. 
This may reflect loss of somatostatin receptors in the met- 
astatic tumors, removal of the mediator of inhibition of cell 
growth when the tumor is resected, or an effect of the drug 
on tumor growth either by altering local growth promoters 
or reducing tumor blood flow. A reduction in blood flow to 
the tumor induced by SMS 201-995 in patient 3 was dem- 
onstrated through angiography; however, further studies 
are required to establish this conclusively. 
Both insulin and glucagon are inhibited by infusions of 
somatostatin-14. In the fasting state, the inhibition of 
these two hormones coexists with a decrease in the blood 
glucose concentration [61-631. This phenomenon is 
thought to be mediated by the dominant inhibition of glu- 
cagon [64-661. Furthermore, in patients with insulinomas, 
hypcglycemia might be expected since hypoglycemia has 
been seen to increase with SMS 201-995 during insulin 
infusion [64,67]. However, selective inhibition of insulin 
with various analogues of somatostatin appears to offer 
the most promise for treating insulinomas. Mandarin0 et al 
[64] demonstrated in vitro selective pharmacologic effects 
of somatostatin-14 on glucagon, insulin, and growth hor- 
mone secretion. 
The effects of SMS 201-995 on insulin secretion in 
humans is being studied; preliminary data suggest that 
subcutaneous injections of the analogue may inhibit insu- 
lin secretion more than glucagon does in normal subjects. 
This may explain the findings in two of our patients that 
treatment with SMS 201-995 ameliorated their hypogly- 
cemia. In these patients, insulin was inhibited to 75 per- 
cent of basal levels, but glucagon was inhibited to only 30 
percent of basal levels, and the inhibition was transient 
with recovery to near basal levels by 48 hours. With SMS 
201-995, parallel inhibition of C-peptide levels occurred, 
and the ratio of insulin to proinsulin was not altered. This 
indicates that the effects of the analogue were achieved 
through the inhibition of insulin secretion and not through 
a change in the biologically active product; therefore, SMS 
201-995 at these doses may effectively inhibit insulin re- 
lease in certain patients [68-701. However, larger doses 
of SMS 201-995 given more frequently may be necessary 
to control peptide secretion in glucagonoma patients [71]. 
The two patients with benign insulinomas illustrate some 
of the interesting pharmacologic effects of the analogue. 
Clearly hyperinsulinism and consequent hypoglycemia 
were responsive to the inhibitory effects of SMS 201-995, 
which is indicative of a preferential effect of SMS 201-995 
on inhibition of insulin as compared with glucagon secre- 
tion. The insulin inhibitory effect of the analogue enabled 
patients to tolerate longer periods of fasting and main- 
tained their euglycemia throughout a complicated opera- 
tive procedure. 
A similar beneficial effect was observed in a newborn 
with nesidioblastosis. However, we did not have the op- 
portunity to study the infant prior to 95 percent pancrea- 
tectomy, and the effects of SMS 201-995 did not appear 
for several days; however, the use of this drug in 
nesidioblastosis merits further study. The infusion of so- 
matostatin-14 is also capable of inhibiting insulin secretion 
in this syndrome [68]. 
In contrast to these three patients, we found that SMS 
201-995 did not prolong the hypoglycemia-free interval in 
two patients with pancreatic tumors. In both cases, the 
drug inhibited the secretion of glucagon and appeared to 
delay the absorption of nutrients from the gastrointestinal 
tract. The period of fasting was not extended, and blood 
glucose levels did not rise with meals so the frequency 
and intensity of hypoglycemic events were not reduced. A 
case of metastatic insulinoma [69] has been reported in 
which control of the patient’s hypoglycemia could have 
been due to either SMS 201-995 therapy or the fact that 
the tumor appeared to secrete predominantly proinsulin, 
which is less effective than insulin in lowering blood glu- 
cose concentration. 
Patients with organic hyperinsulinism may show im- 
provement if insulin secretion is predominantly sup- 
pressed; however, their condition may deteriorate under 
any of the following conditions: dominant suppression of 
glucagon secretion; inhibition of hepatic glucose produc- 
tion: delay in the absorption of nutrients from the gastroin- 
testinal tract; or enhancement of the action of insulin. The 
effects of SMS 201-995 in each of these states should be 
studied while the blood glucose concentration is carefully 
monitored: In patients with benign single adenomas, sur- 
gical resection of the tumor will remain the treatment of 
choice; however, our cases demonstrate the potential of 
SMS 201-995 in managing hyperinsulinism. Patients with 
multiple adenomas, nesidioblastosis, or malignant insulin- 
omas may benefit from SMS 201-995 in combination with 
more traditional forms of therapy. 
Although recent reports suggest that somatostatin and 
its analogues are potent inhibitors of flushing caused by 
carcinoid tumors [43,44], their therapeutic usefulness is 
limited by their multiple effects on many secretory cells 
and their short duration of action [72,73]. SMS 201-995 
has been used to treat endocrine tumors [8,39,40] associ- 
ated with flushing and diarrhea. 
Most carcinoid tumors arise from enterochromaffin cells 
of the gut, which contain granules of serotonin, substance 
P, and motilin, and are heterogeneous, multipotential le- 
sions that may secrete many humoral agents. Calcitonin, 
motilin, vasoactive intestinal peptide, ACTH, enter- 
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oglucagon, and substance P are found in carcinoid tumor 
tissue extracts and in the serum of some patients with 
carcinoid syndrome. Flushing, diarrhea, bronchospasm, 
and right-sided heart failure have been ascribed mainly to 
serotonin, prostaglandins, and the kinins. Surgical re- 
moval of carcinoid tumors is the treatment of choice; when 
they are metastatic, chemotherapy is used. In addition to 
the antineoplastic drugs, several pharmacologic agents 
have been used to block the effects of these peptides. 
Parachlorophenylalanine, alpha-methyldopa [74,75], cy- 
proheptadine, methotrimeprazine, and methysergide ma- 
leate are specific to serotonin and are used to control 
flushing, diarrhea, and bronchospasm. Corticosteroids 
block kallikrein release but are rarely effective. Aprotinin, 
a kallikrein trypsin inhibitor, and epsilonamino caproic acid 
have been used to manage refractory hypotension and 
bronchospasm in carcinoid crisis. Phenoxybenzamine 
and antihistamines are used occasionally [34-38,74,76- 
78]. 
Somatostatin has been shown to inhibit diarrhea and 
bronchospasm in patients with carcinoid syndrome and to 
inhibit pentagastrin-induced flushing [43,79]. Davis et al 
[80] investigated the effect of somatostatin infusion on je- 
junal water and electrolyte transplant in a patient with se- 
cretory diarrhea due to malignant carcinoid syndrome. Net 
secretion was inhibited, and absorption was stimulated. In 
our nine patients with the carcinoid syndrome, flushing 
and diarrhea were readily controlled with low doses of 
SMS 201-995. In contrast, we found no effect on circulat- 
ing serotonin levels and in one patient a rise in a biologi- 
cally inert ACTH to 100 times that of normal occurred, 
without the development of Cushing’s syndrome. Tumors 
did not grow during the three to six months of treatment, 
and in two patients the tumors actually seemed to shrink. 
In studies of perfused small intestine of three patients, 
SMS 201-995 induced net water and electrolyte absorp- 
tion in two; therefore, it was not surprising that all our pa- 
tients with secretory diarrhea showed improvement during 
therapy with SMS 201-995 [81,82]. However, when steat- 
orrhea occurred, pancreatic supplements were needed. 
Our experience with SMS 201-995 therapy in a patient 
with diabetic diarrhea unresponsive to conventional drug 
treatment was most interesting. Somatostatin was consid- 
ered because it affects both epithelial transport and intes- 
tinal motility [79]. Native somatostatin as well as the ana- 
logue are known to effectively reduce stool output in diar- 
rhea syndrome associated with endocrine tumors [80,83- 
85] and other conditions [86-891. SMS 201-995 retains 
the critical portion of the molecule Phe-Trp-Lys-Thr13 for 
gut-specificity [88], and reportedly changed net water 
movement to absorption in a patient with severe secretory 
diarrhea due to pancreatic cholera syndrome [89]. In con- 
trast to vipoma patients [83,84,89], the patient with dia- 
betic diarrhea did not over-secrete water or electrolytes; 
nevertheless, subcutaneous injection of the drug did en- 
hance the net absorption of water and electrolytes at the 
peak (30 minutes) SMS 201-995 concentration [89]. 
The possibility that fasting hypoglycemia and postpran- 
dial hyperglycemia will develop in diabetic patients receiv- 
ing long-term therapy with SMS 201-995 is of concern 
[go]. A single SMS 201-995 subcutaneous injection in 10 
patients with insulin-dependent diabetes mellitus reduced 
the insulin dose without causing postprandial hyperglyce- 
mia or hypoglycemia [go]. In our diabetic patient, the insu- 
lin dose required to maintain relative normoglycemia was 
constant over four months of treatment with the analogue, 
but her food intake and cessation of diarrhea may have 
necessitated an increase in insulin. Long-term SMS 201- 
995 treatment of brittle diabetic patients with autonomic 
neuropathy of the gut may stabilize the diabetic control by 
suppression of counterregulatory hormones and en- 
hancement of the absorption of nutrients from the intes- 
tine. 
In the patient with incapacitating diarrhea refractory to 
all medications, SMS 201-995 reduced the volume and 
frequency of stools, and enabled the patient to return to a 
fairly normal life-style. Thus, for some patients with “dia- 
betic diarrhea” unresponsive to available therapy, the 
analogue may be useful adjunctive treatment. 
In summary, in these studies we have demonstrated a 
variety of responses to SMS 201-995. 
l In three patients with benign gastrinomas, the drug 
decreased acid and gastrin secretion that had been un- 
controllable with He-receptor blocking drugs. 
l In two patients with metastatic gastrinoma, the tumors 
continued to grow and gastrin levels could not be reduced 
despite very large doses of the analogue. 
l Three patients with benign insulinoma maintained 
euglycemia with SMS 201-995 therapy, as did a neonate 
with nesidioblastosis. Two elderly patients did not experi- 
ence prolongation of their hypoglycemia-free interval. 
l The response in carcinoid syndrome was variable. 
Flushing and diarrhea were readily controlled, sometimes 
necessitating the use of pancreatic supplements. Tumor 
growth appeared to be relatively refractory to the drug, but 
in selected instances there appeared to be some degree 
of regression or arrest of further growth. There was, how- 
ever, no correlation between hormone or amine output 
and the clinical response or the growth of the tumor. 
l The analogue controlled diarrhea and decreased vas- 
oactive intestinal peptide levels in two patients with 
vipoma syndrome. The tumor infarcted in one patient, an 
effect that may be related to the vascular effects of the 
drug. Diabetic diarrhea could be controlled with SMS 201- 
995 without changing diabetic control when all other forms 
of intervention had failed. 
Our investigations have led us to the following conclu- 
sions: 
l SMS 201-995 controls gastroenteropancreatic tumor 
symptomatology in most patients. 
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. Hormonal responses to the somatostatin analogue do ment with the analogue and pancreatic enzyme replace- 
not always parallel clinical responses. ment may be required. 
l The analogue’s effect on gastroenteropancreatic l Occasionally, a patient may have a local skin reaction 
tumor growth and secretion is variable. to SMS 201-995, but the drug will not have to be with- 
. SMS 201-995 controls diarrhea due to carcinoid tu- drawn. 
mors, vipomas, and diabetes. l SMS 201-995 may result in tumor infarction through 
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Dr. G.W. Geelhoed: What are your thoughts on the use 
of SMS 201-995 as antineoplastic therapy, particularly in 
view of its relative non-toxicity? Further, can it be used as 
a substitute for conventional, first-line antineoplastic ther- 
apy? 
Dr. Aaron I. Vinik: I don’t think we know the answer. I 
think SMS 201-995 is an important therapeutic agent for 
certain tumor situations. The decision to use the drug is 
easy when the patient has not shown a response to cyto- 
toxic therapy. Although the neuroendocrine tumors are 
largely indolent, patients with hepatic metastases have an 
increased mortality. Therefore, in my opinion, those who 
fail to show a response to chemotherapy should be given 
a trial with SMS 201-995. 
Dr. Geelhoed: If I may expand on this, would you recom- 
mend using SMS 201-995 in combination with conven- 
tional treatment in patients in whom symptoms are con- 
trolled, e.g., with H2 antagonists in gastrinoma patients? 
Dr. Vinik: I recommend using SMS 201-995 when 
chemotherapy fails and progression of the tumor is dem- 
onstrated. I cannot, however, recommend it as primary 
therapy until its safety, efficacy, and toxicity have been 
better elucidated. The combination of SMS 201-995 and 
conventional chemotherapy is certainly intriguing, but it is 
much too early to predict what could occur. 
Dr. Attila Et-tan: Would you recommend either low-dose 
or high-dose SMS 201-995 therapy in patients with 
apudoma to prevent hypoglycemia? Further, in our expe- 
rience, there seems to be a discrepancy between the pref- 
erential effects on serum insulin versus glucagon inhibi- 
tion of natural somatostatin versus SMS 201-995. Please 
comment. 
Dr. Vinik: It would be ideal to have a selective somato- 
statin analogue that would suppress insulin but not gluca- 
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Med 1985; 103: 363-367. 
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Discussion 
gon. And in fact, in normal subjects, low doses of SMS 
201-995 may not induce hypoglycemia because of selec- 
tive insulin inhibition. However, in patients with tumors, 
hypoglycemia may be observed with SMS 201-995 be- 
cause of greater sensitivity to glucagon inhibition. Further- 
more, the dose required in tumor patients is much higher. I 
cannot say from our limited experience whether or not the 
observed hypoglycemia will be a function of the benign 
adenomas, multiple adenomas, nesidioblastosis, the ma- 
lignant tumor, or even age. 
Dr. William Y. Chey: Would you elaborate on the use of 
SMS 201-995 in the asymptomatic patient in whom there 
is documented tumor progression? 
Dr. Vinik: At the University of Michigan, all patients with 
metastases receive cytotoxic therapy. If the tumor contin- 
ues to grow, we administer SMS 201-995. At this time, we 
do not consider SMS 201-995 to be a first-line chemother- 
apeutic agent. 
Dr. William B. Malarkey: Could you comment on the 
use of lithium in patients with the watery diarrhea syn- 
drome? 
Dr. Vinik: Based on prior observations that lithium is an 
antidiarrheal agent, we tried it and it worked. However, we 
elected to stop lithium because of its toxicity and to use 
only SMS 201-995, which has minimal toxicity. Although 
combining the two agents could potentiate their effects, 
this has not been established clinically. 
Dr. Manuel Tzagournis: Have vasoactive intestinal 
peptide and other gut hormones been measured in diar- 
rhea1 states besides the water diarrhea syndrome, e.g., 
diabetic diarrhea? Has somatostatin been tried in other 
diarrhea1 states? 
Dr. Vinik: Dr. O’Dorisio can you answer that? 
Dr. Thomas M. O’Dorisio: No, except for true vipomas 
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and their associated watery diarrhea syndrome, and per- 
haps non-tropical sprue wherein vasoactive intestinal 
peptide is sometimes elevated, other casual peptide me- 
diators have not been described. Some secretory diar- 
rheas are not vasoactive intestinal peptide-mediated. 
SMS 201-995 has been used in other states of secretory 
diarrhea; I know that in three of six cases in the United 
States, SMS 201-995 alleviated the diarrhea. One of 
these patients (not one of Dr. Vinik’s) had diabetic diar- 
rhea. 
Dr. William H. Daughaday: Did SMS 201-995 affect the 
growth of the child with nesidioblastosis? 
Dr. Vinik: He is growing well, but some steatorrhea de- 
veloped that required pancreatic supplementation. Hope- 
fully, his condition will improve as he grows, as is often the 
case. 
Dr. M. Sue O’Dorisio: I would like to offer a possible 
interpretation to the varied responses of the tumors to 
SMS 201-995. Subsets of metastatic receptors may occur 
naturally for which the analogue may in some cases act as 
an agonist, and in other cases as an antagonist. In addi- 
tion to neuroendocrine tumors, there may be a spectrum 
of tumors, including some having no somatostatin recep- 
tors, others having any of the receptor subclasses, and 
still others having hone. This may explain the observed 
differences in response to the analogue. 
Dr. Vinik: I concur with Dr. Sue O’Dorisio and would ex- 
tend this line of thinking. Not only may the tumor have or 
require a SMS 201-995 receptor, but also the endothelial 
or smooth muscle cells of the tumor blood vessels may 
have a different tissue receptor. 
Dr. Dorothy Becker: No one has mentioned the effects 
of long-term SMS 201-995 therapy on growth hormone or 
other non-pancreatic hormones. We know that SMS 201- 
995 inhibits growth hormone in acromegaly, but what hap- 
pens long-term when children require long-term treatment 
with the analogue, such as your case of nesidioblastosis? 
Dr. Vinik: Your question demands an answer; however, 
we have not had the opportunity to follow these patients 
long-term. 
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